血清IGFBP3、ERCC1与NSCLC患者一线化疗敏感性的关系  

Relationship between Serum IGFBP3,ERCC1 and NSCLC Patients with First-lineChemotherapy Sensitivity

作　　者：张秀芳[1] 张军营 王培[2] ZHANG Xiufang;ZHANG Junying;WANG Pei(Anyang People's Hospital,Anyang,455000)

机构地区：[1]河南省安阳市人民医院,455000 [2]河南省人民医院,450003

出　　处：《实用癌症杂志》2021年第5期785-788,共4页The Practical Journal of Cancer

摘　　要：目的探讨血清胰岛素样生长因子结合蛋白3(IGFBP3)、核苷酸切除修复交错互补基因1(ERCC1)表达与非小细胞肺癌(NSCLC)患者一线化疗敏感性的关系。方法选取一线化疗的NSCLC患者107例,在完成4~6个疗程后,根据WHO实体瘤疗效评估结果分为敏感组77例、不敏感组30例;对比两组化疗前的血清IGFBP3、ERCC1水平,对比化疗敏感组与不敏感组患者的临床病理学资料;采用Logistic多因素分析影响NSCLC患者一线化疗敏感性的相关因素。结果化疗敏感组患者化疗前的血清IGFBP3、ERCC1水平显著高于不敏感组,差异具有统计学意义(P<0.05);化疗敏感组患者与不敏感组患者的TNM分期、肿瘤分化程度比较,差异具有统计学意义(P<0.05);两组年龄、性别、吸烟、病理类型、病灶直径、淋巴结转移情况差异无统计学意义(P>0.05);经Logistic回归分析,TNM分期增高、分化程度降低、血清IGFBP3水平降低、ERCC1水平降低是NSCLC患者采用一线化疗不敏感的独立危险因素(P<0.05)。结论化疗前的血清IGFBP3、ERCC1水平降低可能是NSCLC患者一线化疗效果不佳的危险因素之一。Objective To investigate the relationship between serum insulin-like growth factor binding protein 3(IGFBP3),nucleotide excision repair cross-complementing gene 1(ERCC1)expression and first-line chemotherapy sensitivity in patients with non-small cell lung cancer(NSCLC).Methods 107 patients with NSCLC who underwent first-line chemotherapy were selected.After completing 4 to 6 courses of treatment,they were divided into sensitive group 77 cases and insensitive group 30 according to WHO solid tumor efficacy evaluation results.The serum levels of IGFBP3 and ERCC1 before chemotherapy were compared between the 2 groups.The clinical and pathological data of patients with chemotherapy-sensitive and insensitive groups were compared.Logistic multivariate analysis was used to analyze the factors related to the sensitivity of first-line chemotherapy in patients with NSCLC.Results The levels of serum IGFBP3 and ERCC1 in the chemotherapy-sensitive group were significantly higher than those in the insensitive group(P<0.05).The difference between TNM stage and tumor differentiation in patients with chemotherapy-sensitive and insensitive groups was statistically significant(P<0.05).There was no significant difference in age,gender,smoking,pathological type,lesion diameter and lymph node metastasis between the 2 groups(P>0.05).Logistic regression analysis showed that increasing TNM stage and lower differentiation,decreasing serum IGFBP3 levels,and decreasing ERCC1 levels were independent risk factors for first-line chemotherapy in patients with NSCLC(P<0.05).Conclusion Decreased serum levels of IGFBP3 and ERCC1 before chemotherapy may be one of the risk factors for poor first-line chemotherapy in patients with NSCLC.

关 键 词：胰岛素样生长因子结合蛋白3 核苷酸切除修复交错互补基因1 非小细胞肺癌 一线化疗 敏感性 

分 类 号：R734.2[医药卫生—肿瘤]